by Elena Iemma | Feb 27, 2025 | News
EpiVax Strengthens Technology Leadership Amid Immunoinformatics Advancements PROVIDENCE, R.I., Feb. 27, 2025 — EpiVax, Inc. proudly announces the appointment of Guilhem Richard as Chief Technology Officer. Dr. Richard joined EpiVax’s immunoinformatics team in 2014 and...
by Elena Iemma | Oct 24, 2024 | News
PROVIDENCE, R.I., Oct. 24, 2024 /PRNewswire/ — EpiVax, Inc. and CUBRC, Inc. announce today that they have been awarded a two-year, $2 million contract (#75F40124C00094) from the Office of Generic Drugs (OGD) of the Food and Drug...
by Elena Iemma | Aug 18, 2024 | Blog
Immunogenicity Risk Assessment: In Silico, In Vitro, and What’s Next Don’t Miss This one! Put this one on your calendar: Scientific and Regulatory Considerations for Assessment of Immunogenicity Risk … The gang will all be...
by Elena Iemma | Aug 10, 2023 | News
PROVIDENCE, RI, August 10, 2023 /PRNewswire/ — EpiVax Inc. announces the publication of results from a research collaboration with the Food and Drug Administration aimed at streamlining generic drug evaluations. The research, initiated in 2018 with a $1M...
by Elena Iemma | Jan 26, 2021 | Events, Webinars
The FDA hosted a virtual workshop January 26, 2021 to provide updates and foster discussions around non-clinical assays for comparative immunogenicity risk assessment of generic peptide products. EpiVax CEO/CSO, Annie De Groot, presented an update on EpiVax’s...